Clinical trial
QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain…
NCT00385398 · University of Medicine and Dentistry of New Jersey, Other · Withdrawn
Key facts
| NCT number | NCT00385398 |
|---|---|
| Title | QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC |
| Official title | Phase II Quality of Life Study of Stereotactic RadioSurgery, Temozolomide and Erlotinib Chemotherapy for the Treatment of 1-3 Brain Metastases in Non-small Cell Lung Cancer |
| Lead sponsor | University of Medicine and Dentistry of New Jersey, Other |
| Collaborators | National Cancer Institute (NCI) NIH Schering-Plough Industry Genentech, Inc. |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, Metastatic Cancer |
| Intervention type | Drug, Radiation |
| Interventions | erlotinib hydrochloride, temozolomide, stereotactic radiosurgery |
| Enrollment | 0 |
| Start date | Jul 1, 2008 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Oct 9, 2006 |
| Last update posted | Sep 2, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: